Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER‐based population study with propensity‐matched comparative analysis. (14th August 2022)

• Record Type: Journal Article
• Authors: Zhang, Chengkai; Zhang, Yuan; Li, Deling; Jia, Wang
• Is Part Of: Cancer medicine. Volume 12:Number 3(2023)
• Page Start: 2677
• Page End: 2690
• Publication Date: 2022-08-14
• Subjects: brain metastases -- primary tumor surgery -- SEER -- survival benefits; 616.994005
• DOI: 10.1002/cam4.5142
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: Evidence about the prognostic value of primary tumor surgery (PTS) in patients with brain metastatic malignancies is ambiguous and controversial. This study assessed the survival benefits of primary tumor surgery in patients with brain metastases (BMs). Methods: Adults patients with BMs that originated from lung, breast, kidney, skin, colon, and liver diagnosed between 2010 and 2018 were derived from the Surveillance, Epidemiology, and End Results database (SEER). Propensity score matching (PSM) was used to balance the bias between patients with or without PTS. Then the prognostic value of PTS was estimated by Kaplan–Meier analysis and Cox proportional hazard regression models. Results: A total of 32, 760 patients with BMs secondary to non‐small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, renal cancer, melanoma, colorectal cancer, and liver cancer were identified from the database. After PSM at 1:1 ratio, PTS appeared to significantly prolong cause‐specific survival (CSS) time for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer (hazard ratio [HR] = 0.60 [0.53–0.68], 0.56 [0.43–0.73], 0.47 [0.37–0.60], and 0.59 [0.37–0.95], respectively, all p < 0.05). Patients with earlier T and N classifications, no extracranial metastasis, and cancer‐specific subtypes (adenocarcinoma in NSCLC, hormone receptor‐negative breast cancer) may derive more survival benefits from PTS when suffering from BMs. Conclusion: This population‐based study supported PTS could provide survival benefits for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer. More emphasis should be put on PTS of selected patients with BMs. Abstract : This SEER‐based study assessed the survival benefits of primary tumor surgery (PTS) in patients with brain metastases (BMs). PTS appeared to significantly prolong cause‐specific survival (CSS) time for patients with BMs secondary to non‐small cell lung cancer, breast cancer, renal cancer, and colorectal cancer, rather than BMs from small cell lung cancer, melanoma, and liver cancer.